<DOC>
	<DOCNO>NCT02132598</DOCNO>
	<brief_summary>This open-label phase II clinical trial design allow preliminary assessment efficacy safety cabozantinib unselected Non-Small Cell Lung Cancer ( NSCLC ) patient metastases brain subset patient c-MET amplified Non-Small Cell Lung Cancer metastases brain . Previously treated patient non-squamous NSCLC brain metastasis point treatment history eligible enrollment clinical trial . Patients clinically asymptomatic untreated brain metastasis allow trial discretion treat investigator . Patients undergone treatment brain metastases Whole-Brain Radiation Therapy ( WBRT ) , stereotactic radiosurgery ( SRS ) surgery must clinically stable recovered procedure time study enrollment .</brief_summary>
	<brief_title>Trial Cabozantinib ( XL184 ) Non-Small Cell Lung Cancer With Brain Metastases</brief_title>
	<detailed_description>This Phase 2 , single-arm , open-label study cabozantinib subject molecularly unselected Non-Small Cell Lung Cancer ( NSCLC ) metastases brain patient c-MET amplified Non-Small Cell Lung Cancer ( NSCLC ) metastases brain . Patients receive cabozantinib 60 mg orally daily continue treatment disease progression , death unacceptable adverse event . Treatment cycle 4 week duration . The primary endpoint Overall Response Rate ( ORR ) unselected NSCLC population molecularly select patient basis c-MET amplification .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>1 . Previously treat patient nonsquamous NSCLC brain metastasis point treatment history eligible enrollment clinical trial . ( Patients must receive least one regimen systemic disease may cytotoxic oral tyrosine kinase inhibitor therapy . ) Patients clinically asymptomatic untreated brain metastasis allow trial discretion treat physician Patients undergone treatment brain metastasis whole brain radiotherapy , stereotactic radiosurgery , surgical resection must clinically stable recovered procedure time study enrollment . 2 . Patients must tumor tissue available submission sufficient complete cMET Fluorescence Situ Hybridization ( FISH ) study well routine molecular profile UPMC . Patients must agree submission specimen define Section 9. cMET amplification determine FISH ratio ( cMET/CEP7 ) &gt; 2.0 , base test primary tumor and/or site metastatic disease Patients ' tumor must undergo test Epidermal Growth Factor Receptor ( EGFR ) exon 19 deletion , EGFR exon 21 L858R substitution , anaplastic lymphoma kinase ( ALK ) rearrangement . If positive , patient must treat appropriate tyrosine kinase inhibitor ( TKI ) prior enrol study . 3 . The subject assessment extracranial disease site ( e.g. , computerize tomography ( CT ) scan , positron emission tomographyCT , bone scan appropriate ) within 28 day first dose cabozantinib . 4 . The subject must baseline brain MRI scan CT scan head ( patient unable obtain MRI ) within 14 day prior first dose cabozantinib . Patients receive glucocorticoid must stable dose glucocorticoid 5 day prior baseline brain imaging . 5 . Patients must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 6 . Subjects undergone recent resection biopsy intracranial tumor eligible long follow condition apply : First dose cabozantinib occurs least 28 day surgery , subject recover effect surgery 7 . Age ≥18 year 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ( Karnofsky ≥60 % ) 9 . Patients must normal organ marrow function define : ( within 4 day begin treatment unless noted otherwise ) Hemoglobin ≥9 g/dL Absolute Neutrophil Count ( ANC ) ≥1,500/mm3 ( CSF support ) Platelets ≥100,000/mm3 Bilirubin ≤ 1.5 x upper limit normal ( ULN ) Bilirubin ( Gilbert 's Disease ) &lt; 3.0 mg/dL Aspartate Aminotransferase ( AST ) ( SGOT ) ≤3.0 × ULN Alanine Aminotransferase ( ALT ) ( SGPT ) ≤3.0 × ULN Serum creatinine ≤ 1.5 x ULN Creatinine clearance ( CrCl ) ≥40 mL/min For creatinine clearance estimation , Cockcroft Gault equation use : Male : CrCl ( mL/min ) = ( 140 age ) × wt ( kg ) / ( serum creatinine × 72 ) Female : Multiply result 0.85 ≤ 1.5 x ULN Lipase ( radiologic clinical evidence pancreatitis ) &lt; 2.0 x ULN Urine protein/creatinine ratio ( UPCR ) ≤1 Serum phosphorus , calcium , magnesium potassium ≥ LLN 10 . The subject capable understanding comply protocol requirement sign informed consent document . 11 . Women childbearing potential must negative serum pregnancy test screening . 12 . The effect cabozantinib develop human fetus unknown . For reason woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry 4 month last dose study drug , even oral contraceptive use . 1 . The subject receive cytotoxic chemotherapy ( include investigational cytotoxic chemotherapy ) biologic agent ( e.g. , cytokines antibody ; include investigational biologic agent ) within 3 week , nitrosoureas/ mitomycin C within 6 week first dose study treatment . 2 . The subject receive prior treatment small molecule kinase inhibitor hormonal therapy ( include investigational kinase inhibitor hormone ) within 14 day five halflives compound active metabolite , whichever longer , first dose study treatment . 3 . Prior treatment cabozantinib cMET direct therapy . 4 . The subject receive radiation therapy follow : To thoracic cavity , abdomen pelvis within 3 month first dose study treatment ongoing complication without complete recovery heal prior radiation therapy To bone brain metastasis within 14 day first dose study treatment To site ( ) within 28 day first dose study treatment 5 . The subject receive radionuclide treatment within 6 week first dose study treatment . 6 . The subject evidence acute intracranial intratumoral hemorrhage either MRI computerize tomography ( CT ) scan . The subject recover baseline CTCAE ≤ Grade 1 toxicity due prior therapy except alopecia nonclinically significant AEs . 7 . The subject prothrombin time ( PT ) / International Normalized Ratio ( INR ) partial thromboplastin time ( PTT ) test ≥ 1.3 x laboratory ULN within 7 day first dose study treatment . 8 . The subject receive concomitant treatment warfarin , warfarinrelated agent , low molecular weight heparin ( LMWH ) time study entry therapeutic dos . Lowdose warfarin ( ≤ 1 mg/day ) LMWH prophylactic dos permit . 9 . The subject receive enzymeinducing antiepileptic agent within 2 week first dose cabozantinib ( e.g. , carbamazepine , phenytoin , phenobarbital , primidone ) . Other enzyme induce agent prohibit within 2 week first dose cabozantinib include rifampin , rifabutin , rifapentin , St. John 's Wort . 10 . The subject experience following : Clinicallysignificant gastrointestinal bleeding within 6 month first dose study treatment b.Hemoptysis ≥ 0.5 teaspoon ( 2.5ml ) red blood within 3 month first dose study treatment Any sign indicative pulmonary hemorrhage within 3 month first dose study treatment 11 . The subject radiographic evidence cavitating pulmonary lesion ( ) 12 . The subject tumor abutting , invade encase major blood vessel . 13 . The subject evidence tumor invade Gastro Intestinal ( GI ) tract ( esophagus , stomach , small large bowel , rectum anus ) , evidence endotracheal endobronchial tumor within 28 day first dose cabozantinib . 14 . The subject uncontrolled , significant intercurrent recent illness include , limited , following condition : Cardiovascular disorder include : Congestive heart failure ( CHF ) : New York Heart Association ( NYHA ) Class III ( moderate ) Class IV ( severe ) time screen Concurrent uncontrolled hypertension define sustain BP &gt; 140 mm Hg systolic , &gt; 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 day first dose study treatment Any history congenital long QT syndrome Any follow within 6 month first dose study treatment : 1.unstable angina pectoris 2.clinicallysignificant cardiac arrhythmia 3.stroke ( include Transient Ischemic Attack ( TIA ) , ischemic event ) 4.myocardial infarction ( MI ) 5.thromboembolic event require therapeutic anticoagulation ( Note : subject venous filter ( e.g . vena cava filter ) eligible study ) Gastrointestinal disorder particularly associate high risk perforation fistula formation include : Any follow within 28 day first dose study treatment 1 . Intraabdominal tumor/metastases invade GI mucosa 2 . Active peptic ulcer disease , 3 . Inflammatory bowel disease ( include ulcerative colitis Crohn 's disease ) , diverticulitis , cholecystitis , symptomatic cholangitis appendicitis 4 . Malabsorption syndrome Any follow within 6 month first dose study treatment : 1 . Abdominal fistula 2 . Gastrointestinal perforation 3 . Bowel obstruction gastric outlet obstruction 4 . Intraabdominal abscess . Note : Complete resolution intraabdominal abscess must confirm prior initiating treatment cabozantinib even abscess occur 6 month first dose study treatment . Other disorder associate high risk fistula formation include Percutaneous Endoscopic Gastrostomy ( PEG ) tube placement within 3 month first dose study therapy . Other clinically significant disorder : Serious active infection require systemic treatment within 28 day first dose study treatment . Serious nonhealing wound/ulcer/bone fracture within 28 day first dose study treatment . History organ transplant Concurrent uncompensated hypothyroidism thyroid dysfunction within 7 day first dose study treatment . History surgery follow : 1 . Subjects undergone recent resection biopsy intracranial tumor eligible long follow condition apply : First dose cabozantinib occurs least 28 day surgery , subject recover effect surgery . 2 . Other minor surgery within 28 day first dose cabozantinib wound heal complication . If evidence wound dehiscence , subject eligible trial minimum 3 month surgery first dose cabozantinib , provide complete wound heal confirm least 28 day first dose cabozantinib . 3 . Other major surgery within 2 month first dose cabozantinib wound heal complication . If evidence wound dehiscence , subject eligible trial minimum 6 month surgery first dose cabozantinib , provide complete wound heal confirm least 28 day first dose cabozantinib . 4 . The subject unable swallow tablet . 5 . The subject correct QT interval calculate Fridericia formula ( QTcF ) &gt; 500 m within 28 day randomization . Note : initial QTcF find &gt; 500 m , two additional EKGs separate least 3 minute perform . If average three consecutive result QTcF ≤ 500 m , subject meet eligibility regard . 6 . The subject pregnant breastfeeding . 7 . The subject previously identify allergy hypersensitivity component study treatment formulation . 8 . The subject unable unwilling abide study protocol cooperate fully investigator designee . 9 . The subject evidence within 2 year start study treatment another malignancy require systemic treatment . Note : Subjects history early stage locally advance nonmetastatic prostate cancer within 2 year start study treatment may include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non Small Cell</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>c-MET</keyword>
</DOC>